Compare Trans Genic Inc. with Similar Stocks
Dashboard
1
Weak Long Term Fundamental Strength with a -155.25% CAGR growth in Operating Profits over the last 5 years
2
Poor long term growth as Operating profit has grown by an annual rate -155.25% of over the last 5 years
3
With a growth in Operating Profit of 182.11%, the company declared Very Positive results in Jun 26
4
With ROE of -6.29%, it has a risky valuation with a 0.74 Price to Book Value
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 3,706 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.01
7.15%
0.78
Revenue and Profits:
Net Sales:
3,659 Million
(Quarterly Results - Jun 2026)
Net Profit:
133 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
21.33%
0%
21.33%
6 Months
-8.9%
0%
-8.9%
1 Year
19.07%
0%
19.07%
2 Years
8.02%
0%
8.02%
3 Years
-10.18%
0%
-10.18%
4 Years
-21.23%
0%
-21.23%
5 Years
-56.46%
0%
-56.46%
Trans Genic Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.20%
EBIT Growth (5y)
-155.25%
EBIT to Interest (avg)
15.64
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
1.65
Tax Ratio
53.02%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
10.75%
ROE (avg)
10.01%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.74
EV to EBIT
-148.28
EV to EBITDA
31.13
EV to Capital Employed
0.77
EV to Sales
0.33
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-0.52%
ROE (Latest)
-6.29%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bearish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
3,659.10
3,479.20
5.17%
Operating Profit (PBDIT) excl Other Income
199.80
74.20
169.27%
Interest
15.70
9.40
67.02%
Exceptional Items
-0.20
-305.40
99.93%
Consolidate Net Profit
132.70
-106.90
224.13%
Operating Profit Margin (Excl OI)
44.70%
9.60%
3.51%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 5.17% vs 0.25% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 224.13% vs -8,123.08% in Mar 2026
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
13,174.40
13,005.10
1.30%
Operating Profit (PBDIT) excl Other Income
293.60
-64.40
555.90%
Interest
45.80
36.60
25.14%
Exceptional Items
-458.40
-373.60
-22.70%
Consolidate Net Profit
-97.50
-1,090.60
91.06%
Operating Profit Margin (Excl OI)
10.50%
-19.60%
3.01%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 1.30% vs -0.60% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 91.06% vs -27,365.00% in Mar 2025
About Trans Genic Inc. 
Trans Genic Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






